STOCK TITAN

ORHub Acquires PUR Biologics, Entering the Global Medical Device Market

(Moderate)
(Neutral)

Rhea-AI Summary

ORHub, Inc. (OTC PINK:ORHB) has acquired 100% equity interest in PUR Biologics, LLC, marking its entry into the global medical device market, projected to reach $445.1 billion by 2026. The acquisition focuses on utilizing PUR's technologies to regenerate cartilage and alleviate pain related to osteoarthritis and degenerative disc disease. With this strategic move, ORHub aims to enhance treatment options and expand its market presence, including updates to corporate branding and potential uplisting.

Loading...
Loading translation...

Positive

  • Acquisition of PUR Biologics provides advanced technologies for cartilage regeneration.
  • Entry into a growing medical device market expected to reach $445.1 billion by 2026.
  • Planned corporate branding update and ticker symbol change to reflect new divisions.

Negative

  • None.

News Market Reaction – ORHB

-10.26%
-10.26% Session move

In the trading session that priced this news, ORHB declined 10.26%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

"PUR's technologies will bring new solutions for pain elimination and osteoarthritis."

IRVINE, CA / ACCESSWIRE / April 25, 2022 / ORHub, Inc. (OTC PINK:ORHB) announced today it has purchased 100% of the equity interest and assets of PUR Biologics, LLC.

ORHub will enter the global medical device market, expected to reach $445.1 billion by 2026. With top categories in the USA including Hip, Knee, & Spine, reaching $75 billion, ORHub will utilize PUR's proprietary technologies to regenerate cartilage, mitigate pain, and address the biological causes of degenerative disc disease and osteoarthritis of joints.

"We plan to offer improved treatments for age-related joint pain and the degeneration of cartilage in orthopedic indications. Technologies like PUR's can enable new ways to address the underlying cause of undesired inflammation and pain signals, while igniting our body's natural healing capabilities," shared CJ Wiggins - Founder, Executive Chairman, President & CEO for ORHub. "We are excited about this acquisition and the opportunity to advance autologous cell and cellular derived therapeutics for osteoarthritis and degenerative disc disease."

"PUR Biologics has cultivated innovative technologies, in addition to our full line of bone regeneration products currently on the market. We have identified and secured intellectual property that will finally address major gaps in medical treatment. ORHub is the ideal acquisition partner, with both the necessary science and business structure to take our technologies to the global market," explained Ryan Fernan, former CEO of PUR Biologics.

With this addition to ORHub, plans are being made to update the corporate branding and ticker symbol to encompass its Digital Technology and Regenerative Therapeutic division as it continues its preparations for an audit and up- listing.

--------------
Additional upcoming information:
For more on ORHub, visit: www.ORHub.com
Connect with ORHub on LinkedIn: linkedin.com/company/orhub
Follow @ORHub on Twitter: twitter.com/orhub

About ORHub, Inc.

ORHub, Inc. (OTC: ORHB) is headquartered in Irvine, California. The company is focused on the Internet of Things (IoT), creating Intelligent Automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHub's solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility.

###

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of ORHub's products and services, the results from use of ORHub's products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHub's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHub's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Company's website at ORHub.com from time to time.

Contact:

Jason Brown
ORHub, Inc.
612-209-7565

SOURCE: ORHUB, Inc.



View source version on accesswire.com:
https://www.accesswire.com/698594/ORHub-Acquires-PUR-Biologics-Entering-the-Global-Medical-Device-Market

FAQ

What is the significance of ORHB's acquisition of PUR Biologics?

The acquisition allows ORHB to enter the global medical device market, leveraging innovative technologies for treating joint pain and degenerative diseases.

What are the expected market impacts of ORHB acquiring PUR Biologics?

The acquisition positions ORHB in a market projected to grow to $445.1 billion by 2026, enhancing its product offerings and competitive edge.

How will ORHB update its branding after the acquisition?

ORHB plans to update its corporate branding and ticker symbol to better encompass its new Digital Technology and Regenerative Therapeutics division.

What are the key technologies involved in PUR Biologics acquisition?

PUR Biologics has proprietary technologies aimed at cartilage regeneration and addressing pain, particularly for osteoarthritis and degenerative disc disease.

When was the acquisition of PUR Biologics announced?

The acquisition was announced on April 25, 2022.